Pfizer puts the pressure on Eli Lilly's JAK inhibitor Olumiant with new data in alopecia areata
As Eli Lilly looks to secure a win for its blockbuster Olumiant in alopecia areata, going where no JAK inhibitor has gone before, Pfizer is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
